Second-generation Bruton s tyrosine kinase inhibitors are a great frontline option for most, if not all, patients with chronic lymphocytic leukemia (CLL), owing to their improved toxicity profiles.
Black patients with cancer are significantly more likely to experience heart damage following chemotherapy than White patients are, a research review indicates.
The latest drugs for chronic lymphocytic leukemia (CLL) offer prolonged remission, along with a need for better tools to gauge their effectiveness: measurable residual disease (MRD) could be useful.
Subcutaneous (SC) administration of fluids and medications offers several benefits and advantages over the intravenous route, but the SC route is rarely used in the United States.